Porcine Elastase (Sus scrofa domesticus)

Porcine elastase is a serine protease derived from pig pancreas (Sus scrofa domesticus) that cleaves elastin and other extracellular matrix proteins at hydrophobic residue sites. It is not used as a human supplement but serves exclusively as a research enzyme to model emphysema and chronic obstructive pulmonary disease in laboratory animals.

Origin & History

Porcine elastase is a serine protease enzyme extracted from the pancreas of domestic pigs (Sus scrofa domesticus), with a molecular weight of approximately 26,400 Da. It is purified from porcine pancreatic tissue using chromatography and precipitation methods to isolate the active enzyme, which belongs to the chymotrypsin family of serine endopeptidases (EC 3.4.21.36).

Historical & Cultural Context

No evidence of traditional use in historical medicine systems was found. Porcine elastase is a modern biochemical tool developed for research purposes, not derived from ethnomedical practices.

Health Benefits

• No documented health benefits in humans - exclusively used as a research tool to induce emphysema in animal models (n=6 pigs, n=9 rats)
• Creates experimental lung damage by degrading elastin, increasing lung compliance by 37.6% in pigs
• Reduces alveolar surface area by ~14% in animal models (P<0.05)
• Used to study emphysema progression and test potential treatments in preclinical settings
• No clinical evidence supporting therapeutic use in humans

How It Works

Porcine elastase functions as a serine protease that cleaves peptide bonds adjacent to small hydrophobic residues such as alanine and valine within elastin, fibronectin, and collagen IV of the extracellular matrix. By degrading alveolar elastin fibers, it disrupts the elastic recoil of lung tissue, activating downstream inflammatory cascades including neutrophil recruitment and matrix metalloproteinase (MMP-2, MMP-9) upregulation. This proteolytic activity increases lung static compliance by disrupting alveolar wall integrity, producing a measurable 37.6% increase in lung compliance in porcine models.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for porcine elastase as a therapeutic agent. Available research consists solely of animal studies using PPE to induce emphysema models, including a study in 6 Yucatan pigs (725-750 U/kg) and rat studies using 400 IU/kg intratracheal administration. No PMIDs were provided in the source material.

Clinical Summary

No human clinical trials exist for porcine elastase as a therapeutic or supplemental intervention. Available evidence derives entirely from animal research, including studies in small cohorts of pigs (n=6) and rats (n=9) where intratracheal instillation was used to induce experimental emphysema. These studies quantified a roughly 14% reduction in alveolar surface area and a 37.6% increase in lung compliance, confirming reliable emphysema induction as a research model. The evidence base is preclinical only, and no dosage, efficacy, or safety data exist for human application.

Nutritional Profile

Porcine Elastase is a purified serine protease enzyme protein derived from porcine (Sus scrofa domesticus) pancreatic tissue. As a highly purified enzymatic preparation, its nutritional contribution is negligible and not intended for nutritional use. Protein content: ~95-98% pure enzyme protein by weight in lyophilized form; molecular weight approximately 25.9 kDa (240 amino acid residues). Macronutrient breakdown per typical research-grade preparation: protein constitutes essentially 100% of dry mass with trace stabilizing excipients (e.g., sodium acetate buffer salts). No carbohydrates, lipids, or dietary fiber are present in purified preparations. Micronutrients: contains catalytic calcium ions (Ca²⁺) at approximately 1 binding site per enzyme molecule, essential for structural stability but not nutritionally significant at research doses (typically 0.1–2.0 U/kg in animal studies). Bioactive compounds: the enzyme itself is the sole bioactive component, with specific activity typically ranging from 1–10 units/mg protein (1 unit defined as hydrolysis of 1 µmol N-succinyl-Ala-Ala-Ala-p-nitroanilide per minute at pH 8.0, 25°C). Amino acid composition reflects typical pancreatic serine protease profile, rich in serine, histidine, and aspartate residues forming the catalytic triad. Bioavailability: not applicable for oral nutritional context; administered via intratracheal instillation or intravenous injection in research settings exclusively. Would be fully denatured and digested if ingested orally, yielding standard amino acids with no intact enzymatic activity.

Preparation & Dosage

No clinically studied dosage ranges exist for human use. In animal research models only: 725-750 U/kg (single intratracheal instillation) in pigs, 400 IU/kg intratracheally in rats. No standardized forms for human supplementation have been developed. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Alpha-1-antitrypsin (inhibitor), eglin-c (inhibitor), neutrophil elastase, pancreatic enzymes, proteolytic inhibitors

Safety & Interactions

Porcine elastase has no established safety profile for human consumption or supplementation, as it is exclusively a laboratory reagent. In animal models, administration causes progressive lung tissue destruction, irreversible alveolar damage, and sustained inflammatory infiltration, indicating significant pathological potential. No drug interaction data, contraindication profiles, or pregnancy safety assessments exist for human exposure. Any incidental human exposure to this enzyme would represent a biosafety concern rather than a therapeutic event, and it should not be confused with digestive enzyme supplements derived from porcine pancreatin.